Mar 8 |
ALX Oncology Holdings Inc (ALXO) Reports Growth Amidst Increased R&D Spending
|
Mar 7 |
ALX Oncology Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
|
Mar 5 |
ALX Oncology Announces Two Evorpacept Clinical Abstracts Accepted for Presentation at the AACR Annual Meeting
|
Jan 3 |
ALX Oncology to Present at the 42nd Annual J.P. Morgan Healthcare Conference
|
Dec 23 |
ALX Oncology: Major Caution Warranted Moving Forward
|
Dec 22 |
7 Small-Cap Stocks That Wall Street Loves for Good Reason
|
Dec 8 |
Jefferies raises ALX Oncology to buy, cites upcoming catalysts
|
Nov 14 |
The Latest Analyst Ratings for ALX Oncology Holdings
|
Nov 14 |
ALX Oncology GAAP EPS of -$1.24 misses by $0.37
|
Nov 13 |
ALX Oncology Holdings Inc (ALXO) Reports Q3 2023 Financial Results and Corporate Developments
|